Payment overview · 2025
General Payments
$461.35
23 reported records · 8 companies
Healthcare provider profile · identity verified
Todd K Schultz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1679682678
Verified facts
What the public records show
CMS Open Payments records show Todd K Schultz, MD received $461.35 in general payments during 2025 across 23 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $99.02 | 21.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.47 | 18.1% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $83.02 | 18.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.84 | 14.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.69 | 10.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $39.20 | 8.5% | 2 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $20.82 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.29 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $461.35 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99.02 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.47 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $83.02 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.69 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.48 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| IMMULITE 1000 Immunoassay System Normalized: immulite 1000 immunoassay system |
Device | Siemens Medical Solutions USA, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 385 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 55 |
| Potassium Chloride | Potassium Chloride | 155 | 51 |
| Metformin Hcl Er | Metformin Hcl | 150 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 47 |
| Omeprazole | Omeprazole | 143 | 43 |
| Losartan Potassium | Losartan Potassium | 135 | 40 |
| Ozempic | Semaglutide | 129 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 43 |
| Trazodone Hcl | Trazodone Hcl | 106 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 103 | 25 |
| Gabapentin | Gabapentin | 93 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 28 |
| Simvastatin | Simvastatin | 91 | 24 |
| Alprazolam | Alprazolam | 87 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 26 |
| Meloxicam | Meloxicam | 80 | 23 |
| Mounjaro | Tirzepatide | 76 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 75 | 22 |
| Sertraline Hcl | Sertraline Hcl | 75 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 14 |
| Jardiance | Empagliflozin | 71 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 18 |
| Clonazepam | Clonazepam | 70 | 13 |
| Carvedilol | Carvedilol | 64 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 17 |
| Spironolactone | Spironolactone | 59 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 14 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 13 |
| Bupropion Xl | Bupropion Hcl | 51 | 16 |
| Allopurinol | Allopurinol | 50 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Tramadol Hcl | Tramadol Hcl | 47 | 12 |
| Lisinopril | Lisinopril | 46 | 13 |
| Januvia | Sitagliptin Phosphate | 44 | 12 |
| Methylprednisolone | Methylprednisolone | 44 | 40 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 13 |
| Chlorthalidone | Chlorthalidone | 39 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 12 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Furosemide | Furosemide | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $461.35 · 23 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AREXVY, Dexcom G6 Transmitter, IMMULITE 1000 Immunoassay System, KRYSTEXXA, Ozempic, REBLOZYL, REPATHA, Rybelsus, SHINGRIX, Veozah, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error